Intermediate Clinical Endpoints
Intermediate Clinical Endpoints is a type of clinical outcome measure that serves as a surrogate marker of a disease process, enabling earlier assessment of treatment effects during the accelerated approval of medical therapies by predicting meaningful patient benefits with reasonable likelihood.
129
Publications
11.1K
Citations
945
Authors
456
Institutions
Publications per year
2017–2026
34
Variants
Intermediate Clinical Endpoint
129
M.B. Leon, Nicolò Piazza, Eugenia Nikolsky et al. · European Heart Journal · 2011 · 1.2K citations · Full text
Medicine, Cardiology, Surgery +17
A. Pieter Kappetein, Stuart J. Head, Philippe Généreux et al. · European Heart Journal · 2012 · 1K citations · Full text
Medicine, Cardiology, Surgery +17
1–5 of 129
945
5
h-index
5
h-index
5
h-index
4
h-index
4
h-index
1–5 of 945
456
Harvard University
Cambridge, United States
10 h-index
22 publications
776 citations
National Cancer Institute
Bethesda, United States
6 h-index
17 publications
2.9K citations
University of California, San Francisco
San Francisco, United States
6 h-index
8 publications
276 citations
Duke University
Durham, United States
6 h-index
7 publications
1.4K citations

University of Minnesota
Minneapolis, United States
5 h-index
5 publications
492 citations

Johns Hopkins University
Baltimore, United States
5 h-index
7 publications
274 citations
Massachusetts General Hospital
Boston, United States
5 h-index
8 publications
333 citations
Erasmus MC
Rotterdam, The Netherlands
4 h-index
46 publications
33K citations
1–8 of 456
Repository · 8 publications · 252 citations
8
h-index
ATS · 4 publications · 111 citations
4
h-index
4 publications · 2.3K citations
4
h-index
3 publications · 186 citations
3
h-index
3 publications · 84 citations
3
h-index
1–5